Aurinia Pharmaceuticals Earnings Calls

Q4 2024 (Upcoming)
Release date Feb 20, 2025
EPS estimate $0.0400
EPS actual -
Revenue estimate 59.945M
Revenue actual -
Expected change +/- 9.85%
Q3 2024 Beat
$0.100 (566.67%)
Release date Nov 07, 2024
EPS estimate $0.0150
EPS actual $0.100
EPS Surprise 566.67%
Revenue estimate 65.06M
Revenue actual 67.771M
Revenue Surprise 4.17%
Q2 2024 Beat
$0.0200 (20.05%)
Release date Aug 01, 2024
EPS estimate $0.0167
EPS actual $0.0200
EPS Surprise 20.05%
Revenue estimate 55.05M
Revenue actual 57.192M
Revenue Surprise 3.89%
Q1 2024 Beat
-$0.0300 (82.35%)
Release date May 02, 2024
EPS estimate -$0.170
EPS actual -$0.0300
EPS Surprise 82.35%
Revenue estimate 47.45M
Revenue actual 50.303M
Revenue Surprise 6.01%

Last 4 Quarters for Aurinia Pharmaceuticals

Below you can see how AUPH performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q1 2024 Beat
Release date May 02, 2024
Fiscal end date Mar 31, 2024
Price on release $5.17
EPS estimate -$0.170
EPS actual -$0.0300
EPS surprise 82.35%
Date Price
Apr 26, 2024 $4.91
Apr 29, 2024 $5.01
Apr 30, 2024 $5.09
May 01, 2024 $5.20
May 02, 2024 $5.17
May 03, 2024 $5.10
May 06, 2024 $5.16
May 07, 2024 $5.12
May 08, 2024 $5.15
4 days before 5.30%
4 days after -0.387%
On release day -1.35%
Change in period 4.89%
Q2 2024 Beat
Release date Aug 01, 2024
Fiscal end date Jun 30, 2024
Price on release $5.61
EPS estimate $0.0167
EPS actual $0.0200
EPS surprise 20.05%
Date Price
Jul 26, 2024 $5.68
Jul 29, 2024 $5.68
Jul 30, 2024 $5.62
Jul 31, 2024 $5.88
Aug 01, 2024 $5.61
Aug 02, 2024 $5.50
Aug 05, 2024 $5.37
Aug 06, 2024 $5.62
Aug 07, 2024 $5.32
4 days before -1.23%
4 days after -5.17%
On release day -1.96%
Change in period -6.34%
Q3 2024 Beat
Release date Nov 07, 2024
Fiscal end date Sep 30, 2024
Price on release $8.34
EPS estimate $0.0150
EPS actual $0.100
EPS surprise 566.67%
Date Price
Nov 01, 2024 $7.32
Nov 04, 2024 $7.21
Nov 05, 2024 $7.32
Nov 06, 2024 $7.52
Nov 07, 2024 $8.34
Nov 08, 2024 $8.32
Nov 11, 2024 $8.49
Nov 12, 2024 $8.38
Nov 13, 2024 $8.28
4 days before 13.93%
4 days after -0.719%
On release day -0.240%
Change in period 13.11%
Q4 2024 (Upcoming)
Release date Feb 20, 2025
Fiscal end date Dec 30, 2024
Price on release -
EPS estimate $0.0400
EPS actual -
Date Price
Feb 06, 2025 $8.09
Feb 07, 2025 $8.01
Feb 10, 2025 $7.97
Feb 11, 2025 $7.61
Feb 12, 2025 $7.81

Aurinia Pharmaceuticals Earnings Call Transcript Summary of Q3 2024

  • Net Product Revenue: Rose to $55.5 million in Q3 2024, representing a 36% increase compared to $40.8 million in Q3 2023.
  • Year-to-Date Performance: First 9 months of 2024 net revenue reached $175.3 million, up 34% from $130.4 million in the first 9 months of 2023, with net product revenue at $158.6 million.
  • Cash Flow: Generated approximately $17 million from operations in Q3 2024. As of September 30, 2024, the company had $348.7 million in cash and equivalents.

Commercial Performance:

  • Prescriber and Patient Metrics: Added 364 prescriber-facing accounts (PSFs) and 146 new patient starts, totaling 510 new engagements. Overall, 2,422 patients are now on LUPKYNIS therapy, a 25% increase year-over-year.
  • Guidance Reaffirmation: The company maintains its product revenue guidance for 2024 at $210 million to $220 million.

Clinical Development:

  • Phase I Study Announcement: The first participant in the Phase I study of AUR200, a BAFF/APRIL dual antagonist, has been dosed, with initial results anticipated in 2025.
  • Regulatory Developments: LUPKYNIS received approval from Japanese authorities, triggering a $10 million milestone payment.

Operational Restructuring:

  • Workforce Reduction: Approximately 45% of the workforce will be cut to enhance operational efficiency and focus on LUPKYNIS and AUR200 development. This is expected to yield annual cost savings of over $40 million.
  • Strategic Focus: The restructuring aims to sharpen commercial and R&D efforts, streamline operations, and strengthen the company's financial position for future growth.

Guidance on Future Developments:

  • Aurinia will focus on the ongoing development of AUR200 and expects to present pharmacokinetic profiles and relevant biomarker data from upcoming clinical trials.
  • The company plans to provide insights from the ENLIGHT-LN registry concerning real-world treatment patterns, particularly in diverse patient populations, to understand how LUPKYNIS is being utilized.

Conclusion:

Aurinia Pharmaceuticals showed promising growth in Q3 2024, both in terms of revenue and patient metrics, and is strategically positioned for continued expansion following a significant operational restructuring. The company remains optimistic about the commercial viability of LUPKYNIS and the advancement of AUR200 into clinical testing. Investors should monitor the impact of these changes and upcoming data releases as the company transitions into 2025.

Aurinia Pharmaceuticals Earnings History

Earnings Calendar

FAQ

When is the earnings report for AUPH?
Aurinia Pharmaceuticals Inc (AUPH) has scheduled its earnings report for Feb 20, 2025 before the markets open.

What is the AUPH price-to-earnings (P/E) ratio?
AUPH P/E ratio as of Feb 12, 2025 (TTM) is -50.56.

What is the AUPH EPS forecast?
The forecasted EPS (Earnings Per Share) for Aurinia Pharmaceuticals Inc (AUPH) for the first fiscal quarter 2024 is $0.0400.

What are Aurinia Pharmaceuticals Inc's retained earnings?
On its balance sheet, Aurinia Pharmaceuticals Inc reported retained earnings of $67.77 million for the latest quarter ending Sep 30, 2024.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT AURINIA PHARMACEUTICALS INC
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada....
GOLDEN STAR
Ticker Change Signal Date
LFUS
$234.72
3.32% Feb 10
ITW
$255.56
0.192% Feb 07
O
OBDC
$15.00
2.20% Feb 07
GGB
$2.95
2.37% Feb 06
BUD
$49.11
6.45% Feb 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE